Neurotrope’s wholly-owned operating subsidiary Neurotrope Bioscience has completed the study design for its confirmatory Phase 2 clinical trial in moderate to severe Alzheimer’s disease. The study was designed in consultation with a team of experts in the AD field. The primary efficacy endpoint is defined as the change in the SIB score between the baseline and the average of weeks 13 and 15. Patients will be randomized 1:1 Bryostatin-1 20ug vs. placebo. The company has assembled a team of expert advisors in the areas of neurology, statistical analysis and clinical trial management in AD. Neurotrope will recruit approximately 30 US sites for participation in the upcoming trial.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.